ChiCTR2200062673 版本V1.1 版本创建时间2022/12/29 11:56:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200062673 

最近更新日期:

Date of Last Refreshed on:

2022-08-15 14:25:28 

注册时间:

Date of Registration:

2022-08-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

一种内镜下可注射的温控水凝胶耦合剂在食管超声中的应用研究

Public title:

An endoscopic injectable thermoresponsive hydrogel as coupling agent for use in esophageal ultrasound

注册题目简写:

English Acronym:

研究课题的正式科学名称:

一种内镜下可注射的温控水凝胶耦合剂在食管超声中的应用研究

Scientific title:

An endoscopic injectable thermoresponsive hydrogel as coupling agent for use in esophageal ultrasound

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

樊超强 

研究负责人:

樊超强 

Applicant:

Chaoqiang Fan 

Study leader:

Chaoqiang Fan 

申请注册联系人电话:

Applicant telephone:

15922781214

研究负责人电话:

Study leader's
telephone:

15922781214

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fcqxhkwjs@126.com

研究负责人电子邮件:

Study leader's E-mail:

fcqxhkwjs@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市沙坪坝区新桥正街183号

研究负责人通讯地址:

重庆市沙坪坝区新桥正街183号

Applicant address:

No.183, Xinqiao street, Shapingba District, Chongqing,China

Study leader's address:

No.183, Xinqiao street, Shapingba District, Chongqing,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

陆军军医大学第二附属医院

Applicant's institution:

Second Affiliated Hospital of Army Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-研第086-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军陆军军医大学第二附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Second Affiliated Hospital of Army Medical University, PLA

伦理委员会批准日期:

Date of approved by ethic committee:

2022-04-29 00:00:00

伦理委员会联系人:

刘丹

Contact Name of the ethic committee:

Liu Dan

伦理委员会联系地址:

陆军军医大学第二附属医院

Contact Address of the ethic committee:

Second Affiliated Hospital of Army Medical University, 183 Xinqiao Main Street, Shapingba District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

陆军军医大学第二附属医院

Primary sponsor:

Second Affiliated Hospital of Army Medical University

研究实施负责(组长)单位地址:

重庆市沙坪坝区新桥正街183号

Primary sponsor's address:

No.183, Xinqiao street, Shapingba District, Chongqing,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军军医大学第二附属医院

具体地址:

重庆市沙坪坝区新桥正街183号

Institution
hospital:

Second Affiliated Hospital of Army Medical University

Address:

183 Xinqiao Main Street, Shapingba District, Chongqing, China

经费或物资来源:

陆军军医大学第二附属医院消化内科

Source(s) of funding:

Gastroenterology Department ,Second Affiliated Hospital of Army Medical University

研究疾病:

食管病变  

Target disease:

Esophageal lesions

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

利用F127开发一种安全有效的内窥镜专用超声耦合剂  

Objectives of Study:

Developing a safe and effective ultrasound coupling agent for endoscopy ultrasound using F127

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄18岁~65岁;
(2)性别不限;
(3)食管病变,需要食管超声内镜检查;
(4)自愿接受并遵守本实验方案,按时接受复查及随访;
(5)签署知情同意书。

Inclusion criteria

(1) Age 18 to 65 years old.
(2) Gender is not limited.
(3) Esophageal lesions requiring esophageal endoscopy ultrasound.
(4) Voluntarily accept and comply with this experimental protocol, and accept review and follow-up on time.
(5) Sign the informed consent form.

排除标准:

(1)妊娠妇女;
(2)心肺功能太差,不能耐受无痛电子超声胃镜检查;
(3)不愿意加入本试验,拒绝签署知情同意书或综合判断依从性较差的病例。

Exclusion criteria:

(1) Pregnant women.
(2) Those whose cardiopulmonary function is too poor to tolerate painless ultrasound gastroscopy.
(3) Cases who do not wish to join this trial, refuse to sign the informed consent form or have poor overall judgment of compliance.

研究实施时间:

Study execute time:

From 2022-08-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-08-01 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

F127组

样本量:

23

Group:

F127 group

Sample size:

干预措施:

使用温控水凝胶作为超声内镜耦合剂

干预措施代码:

Intervention:

Use the thermoresponsive hydrogel as coupling agent for esophageal ultrasound

Intervention code:

组别:

生理盐水组

样本量:

23

Group:

Sanitary saline group

Sample size:

干预措施:

使用生理盐水作为超声内镜耦合剂

干预措施代码:

Intervention:

Use the normal saline as coupling agent for esophageal ultrasound

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

陆军军医大学第二附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

Second Affiliated Hospital of Army Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

安全性评价

指标类型:

主要指标

Outcome:

Safety evaluation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内镜超声图像质量评分

指标类型:

主要指标

Outcome:

Endoscopy ultrasound image quality score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

检查中的不良反应

指标类型:

次要指标

Outcome:

Adverse reactions during the examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床症状

指标类型:

次要指标

Outcome:

Clinical symptoms

Type:

Secondary indicator

测量时间点:

检查前和检查后24小时内

测量方法:

Measure time point of outcome:

before and within 24 hours after the examination

Measure method:

指标中文名:

操作时间

指标类型:

附加指标

Outcome:

Operation time

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

耦合剂用量

指标类型:

附加指标

Outcome:

Coupling agent dosage

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

EUS检查结果及诊断

指标类型:

附加指标

Outcome:

EUS examination results and diagnosis

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中所见病变层次结构

指标类型:

附加指标

Outcome:

Intraoperative view of the lesion hierarchy

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后病理诊断

指标类型:

附加指标

Outcome:

Postoperative Pathological diagnosis

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由樊超强根据计算机随机分组软件(SPSS 26.0)对所有纳入正式研究的受试者统一随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the computer randomization software (SPSS 26.0), all the subjects included in the formal study were randomly grouped by Chaoqiang Fan.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-08-15 14:25:09